Hims & Hers Health (HIMS) Stock Price, News & Analysis

Company Overview

Hims & Hers Health, Inc. is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support. Through secure online questionnaires and video visits, patients receive personalized treatment plans covering conditions such as erectile dysfunction, acne, hair thinning, anxiety and depression. Hims & Hers also distributes supplements, vitamin formulations and topical solutions designed to complement its prescription offerings.

Founded in 2017 by Andrew Dudum and headquartered in San Francisco, Hims & Hers emerged as one of the first telehealth subscriptions focused on consumer-friendly branding and straightforward access to care. In July 2021, the company completed a business combination with a special purpose acquisition company, enabling its public listing on the New York Stock Exchange under the ticker HIMS. Since its inception, Hims & Hers has pursued strategic partnerships and acquisitions to expand its medical and technological capabilities.

Serving customers across the continental U.S., Hims & Hers continues to develop its digital care model by enhancing telehealth platform features, broadening its therapeutic categories and strengthening clinical support. Under the leadership of CEO Andrew Dudum and a team of healthcare and technology executives, the company aims to reduce barriers to medical access while driving scalable growth in the evolving virtual care market.

Key Stats

• Today's Range: $53.02 to $56.76
• 50-Day Range: $41.63 to $66.18
• 52-Week Range: $16.05 to $72.98
• Volume: 23.21 million shs
• Average Volume: 27.14 million shs
• Market Capitalization: $12.05 billion
• P/E Ratio: 66.64
• Dividend Yield: N/A
• Price Target: $38.92
• Consensus Rating: Reduce

Hims & Hers Health Stock Analysis - MarketRank™

Hims & Hers Health scored higher than 56% of companies evaluated by MarketBeat, and ranked 457th out of 951 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Hims & Hers Health has received a consensus rating of Reduce. The company's average rating score is 1.92, and is based on 2 buy ratings, 8 hold ratings, and 3 sell ratings.

Downside Risk

Hims & Hers Health has a consensus price target of $38.92, representing about 27.0% downside from its current price of $53.31.

Amount of Analyst Coverage

Hims & Hers Health has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 79.31%

Earnings Growth

Earnings for Hims & Hers Health are expected to grow by 79.31% in the coming year, from $0.29 to $0.52 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Hims & Hers Health is 66.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 281.41.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hims & Hers Health is 66.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 76.29.

Price to Earnings Growth Ratio

Hims & Hers Health has a PEG Ratio of 3.78. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Hims & Hers Health has a P/B Ratio of 24.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

38.27% of the float of Hims & Hers Health has been sold short.

Short Interest Ratio / Days to Cover

Hims & Hers Health has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hims & Hers Health has recently increased by 6.29%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hims & Hers Health does not currently pay a dividend.

Dividend Growth

Hims & Hers Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

38.27% of the float of Hims & Hers Health has been sold short.

Short Interest Ratio / Days to Cover

Hims & Hers Health has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hims & Hers Health has recently increased by 6.29%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.46

News Sentiment

Hims & Hers Health has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 37 news articles for Hims & Hers Health this week, compared to 35 articles on an average week.

Search Interest

231 people have searched for HIMS on MarketBeat in the last 30 days. This is an increase of 32% compared to the previous 30 days.

MarketBeat Follows

40 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 3% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $78,305,856.00 in company stock.

Percentage Held by Insiders

13.71% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HIMS Stock Analysis - Frequently Asked Questions

How have HIMS shares performed this year?

Hims & Hers Health's stock was trading at $24.18 at the beginning of 2025. Since then, HIMS shares have increased by 120.5% and is now trading at $53.3090.

How were Hims & Hers Health's earnings last quarter?

Hims & Hers Health, Inc. (NYSE:HIMS) announced its quarterly earnings results on Monday, August, 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by $0.01. The company's revenue for the quarter was up 72.6% on a year-over-year basis.
Read the conference call transcript.

Who are Hims & Hers Health's major shareholders?

Hims & Hers Health's top institutional shareholders include State Street Corp (3.15%), Geode Capital Management LLC (2.12%), Jane Street Group LLC and Invesco Ltd. (1.14%). Insiders that own company stock include Melissa Baird, David B Wells, Michael Chi, Alex Bard, Patrick Harrison Carroll, Soleil Boughton, Christopher D Payne, Oluyemi Okupe, Andrew Dudum, Christiane Pendarvis, Anja Manuel, Irene Becklund, Irene Becklund and Lynne Chou O'keefe.
View institutional ownership trends.

How do I buy shares of Hims & Hers Health?

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Hims & Hers Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hims & Hers Health investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 8/04/2025
• Today: 9/24/2025
• Next Earnings (Estimated): 11/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Healthcare
• Current Symbol: NYSE:HIMS
• CIK: 1773751
• Web: www.forhims.com
• Phone: 415-851-0195
• Fax: N/A
• Employees: 1,637
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Hims & Hers Health: $38.92
• High Price Target: $68.00
• Low Price Target: $26.00
• Potential Upside/Downside: -27.0%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.92
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.80
• Trailing P/E Ratio: 66.64
• Forward P/E Ratio: 183.82
• P/E Growth: 3.9
• Net Income: $126.04 million
• Net Margins: 9.63%
• Pretax Margin: 6.91%
• Return on Equity: 26.26%
• Return on Assets: 13.06%

Debt

• Debt-to-Equity Ratio: 1.72
• Current Ratio: 4.98
• Quick Ratio: 4.46

Sales & Book Value

• Annual Sales: $1.48 billion
• Price / Sales: 8.16
• Cash Flow: $0.33 per share
• Price / Cash Flow: 163.84
• Book Value: $2.16 per share
• Price / Book: 24.68

Miscellaneous

• Outstanding Shares: 226,020,000
• Free Float: 185,992,000
• Market Cap: $12.05 billion
• Optionable: Optionable
• Beta: 2.14